Innovative Imaging Solutions Median Technologies offers advanced AI-powered imaging solutions tailored for oncology and metabolic disease diagnosis, presenting a strong opportunity to partner with healthcare providers seeking cutting-edge diagnostic tools to improve early detection and treatment accuracy.

Strong Industry Recognition Recognized as an innovative company and listed on Euronext Growth, Median's reputation can facilitate trust among potential clients and stakeholders, creating opportunities for collaboration in clinical research and healthcare innovation initiatives.

Upcoming Product Launches The recent launch of the eyonis LCS for lung cancer screening at RSNA 2025 positions Median as a leader in early detection technology, making it a compelling prospect for institutions focusing on lung cancer and other oncology screening programs.

Strategic Partnerships Recent collaboration with the FDA and participation in prominent healthcare events indicate a strategic focus on regulatory approval and market expansion, offering a gateway for vendors and collaborators to align with a rapidly growing healthcare innovator.

Financial Stability and Growth With substantial funding of over $28 million and revenues between fifty to one hundred million dollars, Median demonstrates financial stability and growth potential, making it an attractive partner for joint ventures, technology licensing, and large-scale clinical projects.